ljc 10627 has been researched along with 2019 Novel Coronavirus Disease in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bhaskar, A; Chaturvedi, S; Dwivedi, VP; Ghoshal, A; Kumari, A; Mukhopadhyay, S; Pahuja, I; Shaji, A; Verma, A | 1 |
1 other study(ies) available for ljc 10627 and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Biapenem, a Carbapenem Antibiotic, Elicits Mycobacteria Specific Immune Responses and Reduces the Recurrence of Tuberculosis.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; CD8-Positive T-Lymphocytes; COVID-19; Disease Models, Animal; Immunity; Immunologic Factors; Mice; Mycobacterium tuberculosis; Tuberculosis | 2023 |